Extended‐release injectable naltrexone (XR‐NTX): a response to clinical issues raised by Brewer & Streel
Brantley P. Jarvis(Johns Hopkins University), Kenneth Silverman(Johns Hopkins University), Emmanuel Oga(Battelle), Shrinidhi Subramaniam(California State University, Stanislaus), D. Andrew Tompkins(University of California, San Francisco), George E. Bigelow(Johns Hopkins University), August F. Holtyn(Johns Hopkins University)
Cited by 1
Related Papers
Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use Cannabis
|JAMA Network Open|2018|259
Extended‐release injectable naltrexone for opioid use disorder: a systematic review
|Addiction|2018|222
Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end‐points in clinical trials
|Addiction|2011|205
Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users
|Drug and Alcohol Dependence|2020|121
Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid
|Journal of Analytical Toxicology|2018|106